Edgewise Therapeutics (EWTX) Current Assets (2020 - 2026)

Edgewise Therapeutics has disclosed Current Assets across 7 years of filings, most recently posting $509.8 million for Q1 2026.

• Current Assets for Q1 2026 came in at $509.8 million, up 15.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $509.8 million (up 15.03% YoY), and the FY2025 annual result was $543.4 million, up 14.28% from the prior year.
• Current Assets came in at $509.8 million for Q1 2026 at Edgewise Therapeutics, down from $543.4 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $603.3 million in Q2 2025 to a low of $253.3 million in Q2 2022.
• The 5-year median for Current Assets is $443.2 million (2025), against an average of $425.5 million.
• Across the five-year window, Current Assets slipped 19.51% in 2023 and jumped 67.64% in 2024, its largest moves.
• Edgewise Therapeutics' Current Assets stood at $357.0 million in 2022, then retreated by 8.4% to $327.0 million in 2023, then soared by 45.41% to $475.5 million in 2024, then grew by 14.28% to $543.4 million in 2025, then decreased by 6.18% to $509.8 million in 2026.
• The last three Current Assets figures came in at $509.8 million (Q1 2026), $543.4 million (Q4 2025), and $573.9 million (Q3 2025), per Business Quant data.